Trial
NCT00451815
BIIB014 Phase 2a Monotherapy
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
—
Condition
Parkinson's Disease
Intervention
active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-23